KRAS驱动瘤生态系统的机械基础:整合免疫,代谢,微生物和流体微环境之间的交叉通话
概括
基尔斯顿大鼠肉瘤病毒性瘤基因同类 (KRAS) 突变显著塑造瘤微环境 (TME). 了解KRAS驱动的TME变化对于开发有效的癌症疗法和克服治疗耐药性至关重要.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 免疫学 免疫学 免疫学
背景情况:
- 基尔斯顿大鼠肉瘤病毒瘤基因同源 (KRAS) 是最常发生突变的RAS GTPase,约占所有癌症的20%.
- 瘤微环境 (TME) 是由细胞和非细胞组成的复杂生态系统,它影响瘤的启动,进展和治疗反应.
- 独特的TME组合与野生类型与瘤性KRAS相关,并且在针对KRAS的治疗过程中会发生TME变化.
研究的目的:
- 审查KRAS抑制剂研究中的关键发展和挑战.
- 系统地评估KRAS突变如何影响TME,包括免疫抑制,代谢相互作用, stromal重塑和微生物组失调.
- 探索针对KRAS突变癌症中TME相互作用的治疗策略.
主要方法:
- 文献综述综合临床前和临床研究.
- 对KRAS-TME交叉通话的机制性见解的系统评估.
- 探索治疗弱点和组合策略的探索.
主要成果:
- 克拉斯突变协调免疫抑制的TME,代谢共生, stromal重塑和微生物组失调.
- 针对KRAS的疗法诱导TME重新连接,这既带来了挑战,也带来了机遇.
- 在野生类型和瘤性KRAS变体之间观察到不同的TME景观.
结论:
- 解读KRAS依赖的TME架构是精密瘤学的关键领域.
- 通过与KRAS抑制剂结合,针对TME相互作用,提供了有前途的治疗途径.
- 进一步研究KRAS-TME交叉对改善癌症治疗结果至关重要.
更多相关视频
09:52A Mimic of the Tumor Microenvironment: A Simple Method for Generating Enriched Cell Populations and Investigating Intercellular Communication
Published on: September 20, 2016
10.5K
07:46Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
Published on: April 30, 2021
4.9K
相关概念视频
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Adaptive Mechanisms in Cancer Cells
6.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Metastasis
5.7K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.7K
Cancer Stem Cells and Tumor Maintenance
5.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.1K
